Vaccine in Medical Technology

Sanofi Pasteur Submits Supplemental Application for A(H1N1) Pandemic Vaccine to U.S. FDA

LYON, France and SWIFTWATER, Pa., Aug. 7 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY ), announced today the company has submitted to the U.S. Food and Drug Administration (FDA) a supplemental application for licensure...

Landmark Study for GSK's Cervical Cancer Vaccine Published in The Lancet

LONDON, July 7 /PRNewswire/ -- The final analysis of the largest efficacy trial of a cervical cancer vaccine is published today in The Lancet . The study, involving 18,644 women, confirmed GlaxoSmithKline's Cervarix (R) is highly effective at protecting against the two most common cervical cance...

Malaria Vaccine Developer, Sanaria Inc., Receives 2009 Vaccine Industry Excellence Award for Best Early-Stage Vaccine Biotech

ROCKVILLE, Md., June 2 /PRNewswire/ -- The award was announced on April 21, 2009 at the World Vaccine Congress Washington conference. The Vaccine Industry Excellence awards recognize the accomplishments and contributions of companies and individuals working in the vaccine industry. Sanaria was nam...

Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS

- Phase II clinical trial investigating the effectiveness of Intercell's Vaccine Enhancement (VE) Patch in combination with an injectable H5N1 pandemic influenza vaccine started today in the U.S. - The study is fully funded by HHS - this is the second study conducted under a 5 year USD 128 m ...

Novel Vaccine Approach Offers Hope in Fight Against HIV

--Gene Transfer Technology May Lead to an HIV Vaccine-- PHILADELPHIA, May 17 /PRNewswire-USNewswire/ -- A research team may have broken the stubborn impasse that has frustrated the invention of an effective HIV vaccine, by using an approach that bypasses the usual path followed by vaccine dev...

Novavax Completes Enrollment of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial

Completion of enrollment keeps Company on track to report primary study results in third quarter of this year ROCKVILLE, Md., May 15 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX ) announced today that enrollment has been completed in the second Phase II clinical trial of its trival...

PharmAthene to Host a Conference Call and Webcast on Wednesday, April 29th at 4:30 PM to Provide an Update on the SparVax(TM) rPA Anthrax Vaccine Program

ANNAPOLIS, Md., April 28 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP ) a biodefense company developing medical countermeasures against biological and chemical threats, announced today that it will be hosting a conference call for investors on Wednesday, April 29th beginning at ...

Progress Against Malaria and Other Infectious Diseases Among Highlights at Annual Vaccine Conference

BALTIMORE, April 27 /PRNewswire/ -- Global progress toward a malaria vaccine is among the key topics to be presented at the 12th Annual Conference on Vaccine Research (ACVR), sponsored by the National Foundation for Infectious Diseases (NFID) April 27-29, 2009 in Baltimore. The ACVR is the world's...

Phase 1 Trial of Whole-Parasite Malaria Vaccine to Begin

FDA approval for testing in humans watershed moment for unique malaria vaccine approach ROCKVILLE, Md., April 23 /PRNewswire/ -- In a move that highlights the strength of public-private collaboration in tackling international health challenges, the Maryland-based company Sanaria I...

Nobilon Advances First Vaccine Into Human Trials - Intranasal Influenza Vaccine Begins Phase I Clinical Development

BOXMEER, Netherlands, March 13 /PRNewswire-FirstCall/ -- Nobilon, the human vaccine business unit of Schering-Plough Corporation (NYSE: SGP ), today announced that it has reached an important milestone with the initiation of its first-in-human clinical development program for SCH 900795, a new...

Children's Hospital Receives $6.7 Million Grant From Gates Foundation to Study Influenza Vaccine in Pregnant Women in Asia

CINCINNATI, Feb. 24 /PRNewswire-USNewswire/ -- Cincinnati Children's Hospital Medical Center has received a $6.7 million grant from the Bill & Melinda Gates Foundation to help prevent flu in pregnant women and their infants in rural areas around the world. Most childhood deaths occur in...

GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA

ATLANTA, Feb. 20 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based, publicly traded biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, announced the first injections...

Novavax Reports Positive Preclinical Results for a Novel, Broadly Cross-Protective H5N1 Pandemic Influenza Virus-like Particle (VLP) Vaccine Candidate

Results support that Novavax's Recombinant Technology May Offer a Powerful, New Approach for Development of the Next Generation of Influenza Vaccines with Broad Protection Against Multiple Strains ROCKVILLE, Md., Feb. 19 /PRNewswire-FirstCall/ -- NOVAVAX (Nasdaq: NVAX ) announced today favo...

Sanofi Pasteur Dengue Vaccine Enters Pediatric Efficacy Clinical Study

LYON, France, February 18 /PRNewswire-FirstCall/ -- - Global Clinical Study Program Across Dengue Endemic Regions in Latin America and Asia Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT : SAN and NYSE : SNY), announced today that its investigational tetr...

Novavax Presents Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program at World Health Organization Conference

VLP Vaccine - Coupled with Innovative Manufacturing - Has Potential to Address Gaps in Global Pandemic Preparedness ROCKVILLE, Md., Feb. 17 /PRNewswire-FirstCall/ -- At the 5th World Health Organization Meeting on Evaluation of Pandemic Influenza Prototype Vaccines in Clinical Trials, Novavax...

Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile

LYON, France, February 17 /PRNewswire-FirstCall/ -- Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT : SAN and NYSE : SNY), announced today that it is sponsoring a phase II clinical study of a vaccine against Clostridium difficile, which is among the most common causes o...

Intercell AG Partners with Inclinix to Enroll 1800 Volunteers for Phase III Travelers' Diarrhea Vaccine Study

WILMINGTON, N.C., Jan. 19 /PRNewswire/ -- Intercell AG has retained Inclinix, Inc., to recruit volunteers for their Phase III clinical trial of a Travelers' Diarrhea (TD) vaccine system. The TD vaccine is in the form of a skin patch -- a novel method for delivering a vaccine that is especiall...

USD 12.5 m Funding for the Development of Intercell's Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)

VIENNA, Austria, Dec. 11 /PRNewswire/ -- Intercell AG (VSE: ICLL) today announced the execution of a contract modification with the U.S. Department of Health and Human Services (HHS). The agreement commits additional funding of USD 12.5 m for Intercell's Pandemic Influenza program. Interc...

Novavax Announces Top Line Results of Phase IIa Clinical Trial for Its Seasonal Influenza VLP (Trivalent) Vaccine Candidate

Favorable immunogenicity results for seasonal vaccine program follows positive results from its pandemic influenza vaccine Phase IIa trial in July 2008; plans to initiate a study of the seasonal vaccine in the elderly in 2009 ROCKVILLE, Md., Dec. 11 /PRNewswire-FirstCall/ -- Novavax, Inc...

SARS Vaccine Achieves Neutralizing Responses in First U.S. Human Trial

SAN DIEGO, Dec. 9 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL ) today announced that results from a Phase I clinical trial of a DNA vaccine for severe acute respiratory syndrome (SARS), conducted by the National Institutes of Health (NIH) and published in the November 25 issue of ...

Two New Studies in the New England Journal of Medicine Show Malaria Vaccine Candidate Advancing in Africa

NEW ORLEANS, Dec. 8 /PRNewswire/ -- Results published online today in the New England Journal of Medicine revealed that the world's most clinically advanced malaria vaccine candidate provides both infants and young children with significant protection against malaria. Two separate phase II trials ...

Novavax Announces Preclinical Data for Respiratory Syncytial Virus Vaccine Candidate

Novavax's first vaccine candidate for the prevention of RSV ROCKVILLE, Md., Dec. 8 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX ) announced today that Dr. Trudy Morrison, PhD, Professor of Molecular Genetics and Microbiology, University of Massachusetts Medical School , will b...

Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children

COLLEGEVILLE, Pa., Dec. 3 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE ), announced today that it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMEA) for approval to market its investigational 13-valent pneumococcal...

The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness

KVISTGARD, Denmark, December 1 /PRNewswire-FirstCall/ -- Following a Request for Proposal issued in 2007 with the intent to procure an MVA-based, third generation smallpox vaccine, Public Works and Government Services Canada, on behalf of the Canadian Department of National Defence, has awarde...

GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America

ATLANTA, Dec. 1 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based biotechnology company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, announced today that the launch of its Phase 2a Human Va...

Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial

SAN DIEGO, Dec. 1 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL ) announced today the receipt of a $1.0 million milestone payment from Merck & Co., Inc. based on Merck's planned initiation of a Phase I clinical trial of an investigational plasmid DNA (pDNA) cancer vaccine. The c...

Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial

SAN DIEGO, Nov. 12 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL ) announced today that the company has completed enrollment of subjects in a Phase 2 trial of its therapeutic DNA vaccine designed to prevent cytomegalovirus (CMV) reactivation and disease in immunosuppressed stem c...

U.S. Navy and U.S. Army to Develop Dengue DNA Vaccine Formulated With Vical's Vaxfectin(R) Adjuvant

SAN DIEGO, Nov. 6 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today announced that the Naval Medical Research Center (NMRC) plans to conduct preclinical and Phase 1 evaluation of a dengue DNA vaccine formulated with the company's Vaxfectin(R) adjuvant and delivered with the Bio...

Nventa Presents Findings on Proprietary Toll-like Receptor 3 (TLR3) Agonist, Poly-ICR, at World Vaccine Congress

Findings Confirm Potency of Poly-ICR as Vaccine Adjuvant SAN DIEGO, Oct. 8 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) today presented positive data from preclinical studies using its proprietary Toll-like Receptor 3 agonist, Poly IC-Poly Arginine (Poly-I...

Research Attributes Lack of HIV/AIDS Vaccine to Use of Chimpanzees

BOSTON, Oct. 6 /PRNewswire-USNewswire/ -- "A return to the use of chimpanzees in AIDS research and vaccine development is without scientific justification," according to a paper released today in the journal Alternatives to Laboratory Animals (ATLA). "An Assessment of the Role of Chimpanzees i...

Multi-Pronged Therapeutic Cancer Vaccine Regimen to be Studied in Melanoma Patients

PARIS, and TORONTO, Sept. 17 /PRNewswire/ -- Sanofi pasteur, the vaccines division of the sanofi-aventis Group, announced today that it is sponsoring a Phase II clinical study exploring a multi-pronged treatment approach to high risk and advanced-stage melanoma -- an often fatal form of cancer...

Successful Results for Mymetics Corporation's Mucosal HIV/AIDS Vaccine Viral Challenge Significantly Exceeds Expectations

NYON, Switzerland, September 16 /PRNewswire-FirstCall/ -- Mymetics Corporation (OTCBB: MYMX), a vaccine development company, is pleased to announce their preliminary SHIV challenge results on non-human primates previously immunized with the Company's mucosal HIV-AIDS vaccine designed for trigg...

DNA Vaccine Developed at the Karmanos Cancer Institute Fights HER2-Positive Cancers

DETROIT, Sept. 15 /PRNewswire-USNewswire/ -- Researchers at the Barbara Ann Karmanos Cancer Institute and Wayne State University School of Medicine have developed a HER2 DNA vaccine that has shown to be effective on drug resistant tumors in mice. The study was reported in the September 15 issu...

Data Suggest CEL-SCI's CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis

VIENNA, Va., Sept. 5 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (Amex: CVM ) announced today that it presented new rheumatoid arthritis data at the Marcus Evans conference on Immunogenicity in Amsterdam. The data, presented by Dr. Daniel Zimmerman, Senior Vice President of Research, Cellul...

Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. aureus Infection

VIENNA, Austria, Aug. 28 /PRNewswire/ -- Intercell AG (VSE: ICLL) today announced that its collaborator Merck & Co., Inc. has initiated a Phase II clinical trial of V710, an investigational vaccine for the prevention of Staphylococcus aureus (S. aureus) infections. This randomized double blind...

Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program

VLP Vaccine - Coupled with Innovative Manufacturing - Has Potential to Address Gaps in Global Pandemic Preparedness ROCKVILLE, Md., Aug. 26 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX ) announced today favorable results from the second stage of the Phase I/IIa human cl...

BioVex Announces Regulatory Clearance to Commence a Clinical Study With ImmunoVEX HSV2; A Vaccine Candidate for Genital Herpes

WOBURN, Mass., Aug. 20 /PRNewswire/ -- BioVex Inc, a biotechnology company developing clinical stage treatments for cancer and the prevention of infectious disease, today announced the UK Medicines and Healthcare products Regulatory Agency (MHRA) has accepted BioVex's Clinical Trial Applicatio...

Karolinska Institutet to Test Vical's Vaxfectin(R) Adjuvant With Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control

SAN DIEGO, Aug. 19 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL ) today announced a research collaboration with the Karolinska Institutet (KI), a leading European medical university, and the Swedish Institute for Infectious Disease Control (SMI), a governmental expert agency, to...

Karolinska Institute to Test Vical's Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control

SAN DIEGO, Aug. 19 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL ) today announced a research collaboration with the Karolinska Institute, a leading European medical university, and the Swedish Institute for Infectious Disease Control (SMI), a governmental expert agency, to evalu...

Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US

SWIFTWATER, Pa. and LYON, France, Aug. 1 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of sanofi-aventis Group, began shipping influenza vaccine (Fluzone(R), Influenza Virus Vaccine) in the United States for the 2008-2009 season. The first 1.3 million doses of influenza vaccine began s...